Objectives: There is only limited information on the antimicrobial susceptibilities and resistance genes of Ureaplasma parvum in South Africa. This study was designed to detect and characterize resistance genes in U. parvum.
Introduction
There is only limited information on antimicrobial susceptibilities and resistance development in Ureaplasma parvum. Only nine Ureaplasma urealyticum and three U. parvum tetracycline-resistant strains that are concurrently resistant to doxycycline have been described. 1 -3 The characterization of tet(M) genes present in ureaplasmas from South Africa has revealed that they can be highly mosaic in structure. 3 Fluoroquinolone resistance has been reported to be associated with gene mutations in DNA gyrase and topoisomerase IV in six strains. 2, 4, 5 Mutations in 23S rRNA 6 or in ribosomal protein L4 and L22 genes 2, 7 have been associated with macrolide resistance development in 19 strains. Lu et al. 8 reported that 21/72 U. urealyticum strains harboured erythromycin ribosome methylase (erm) and 31/72 had macrolide/streptogramin resistance (msr) genes.
This report describes antibiotic susceptibility profiles of U. parvum strains isolated in South Africa and antibiotic resistance genes associated with resistance development or gene acquisition.
Materials and methods

Clinical isolates
One hundred and fifty-seven vaginal swabs (Dacron) were collected from consenting women presenting for termination of pregnancy at the Dr George Mukhari Tertiary Hospital, Pretoria, during the period 2009-10. The ethics approval reference number for the study is MREC/P/60/2009:IR.
DNA was extracted using the High Pure PCR Template Preparation Kit (Roche) as for the isolation of nucleic acids from bacteria and U. parvum PCR detection was performed.
9 PCR detected U. parvum and U. urealyticum in 31 and 5 specimens, respectively, which were then processed for isolation and preliminary identification in U9 broth (Bio-Rad) and ATCC specific broths, 3 with preliminary screening using the SIR Mycoplasma Kit (Bio-Rad). Fifteen presumptive U. parvum isolates were obtained and resubjected to PCR detection/identification confirmatory testing. No Mycoplasma hominis contamination was detected.
Determination of MICs
MICs of tetracycline, doxycycline, ofloxacin, erythromycin, azithromycin and josamycin (Sigma) were determined by microbroth dilution. 10 CLSI breakpoints as for U. urealyticum 11 were used: quinolones, susceptible ≤2 mg/L and resistant ≥4 mg/L; tetracyclines, susceptible ≤1 mg/L and resistant ≥2 mg/L; and macrolides, susceptible ≤4 mg/L and resistant ≥16 mg/L. DNA extraction, resistance gene amplification and sequencing U. parvum DNA was extracted from culture medium using the High Pure PCR Template Preparation Kit (Roche), and antibiotic resistance gene regions were amplified employing the following primers and conditions. For amplification and sequencing of a 1700 bp region of tet(M), the primers tetMF and tetMR, 1 and tetMF and tetMR 2123 were used. 2 An int-Tn gene region associated with transposon Tn1545 was amplified as described by de Barbeyrac et al. 12 For quinolone resistance gene amplification, the primer pairs gyrA-1 and gyrA-2, gyrB-3 and gyrB-4, parC-5 and parC-6, and parE-7 and parE-8, as described by Bebear et al., 13 were used. The primers used for the macrolide resistance gene regions were as follows: operons of 23S rRNA, primer pairs MH23S-11 and UP23S-OP1, and MH23S-11 and UP23S-OP2R2; L4 protein, UPL4-U and UPL4-R; and L22 protein, UPL22-U and UPL22-R. 2 The ribosomal RNA methyltransferase primers erm(A), erm(B), erm(C) and erm(E), and the macrolide/streptogramin resistance primers msr(A), msr(B), msr(C) and msr(D) were used as described by Xiao et al.
7
The PCR products were prepared for sequencing using the Wizard w SV Gel and PCR Clean-Up System (Promega). Purified DNA samples were sequenced at the Central Analytical Facility, University of Stellenbosch, and analysed using Chromas 1.45 and Bioedit 7.0.5 software. Predicted PCR products from ATCC cultures (U. parvum ATCC 27815 and U. urealyticum ATCC 27618) and sequences obtained from clinical strains were compared with corresponding regions obtained through BLAST searches for U. parvum (GenBank accession number: CP000942.1), U. urealyticum (GenBank accession number: AAYN02000002.1), and for tet(M) sequence comparisons Streptococcus pneumoniae (GenBank accession number: X90939.1), Neisseria gonorrhoeae 6418 (GenBank accession number: L12241) and U. urealyticum SV9-Seattle (GenBank accession number: U08812). The int-Tn sequences were compared with S. pneumoniae Tn1545 int-Tn (GenBank accession number: X61025). Sequences of resistant strains were compared with four U. parvum serovars [serovar 1 (ATCC 27813), serovar 3 (ATCC 27815), serovar 6 (ATCC 27818) and serovar 14 (ATCC 33697)].
Results
Seven U. parvum strains were susceptible to all the antibiotics tested and all strains were susceptible to josamycin. On alignment and comparison of the tet(M) gene sequences of the five tetracycline-resistant U. parvum strains with GenBank strains N. gonorrhoeae 6418, S. pneumoniae and U. urealyticum SV9-Seattle, the leader 600 nucleotides including Govender et al.
the promoter region of the tet(M) gene exhibited diversity with truncated S. pneumoniae and U. urealyticum regions (Figure 1 ). The tet(M) sequences for Up-20, Up-38 and Up-56 were identical, with Up-8 showing 97% similarity. Three different regions were evident for strain Up-15, with only 82% similarity. On characterizing int-Tn genes, strains Up-15, Up-20, Up-38 and Up-56 had identical sequences, which differed from S. pneumoniae Tn1545 int-Tn by 58 nucleotides. The int-Tn of strain Up-8 had the same 58 nucleotide changes as those of the other four strains, but with an additional nucleotide alteration. Sequence comparisons of the ofloxacin-resistant strain (MIC 128 mg/L) were conducted with four U. parvum serovars [serovar 1 (ATCC 27813), serovar 3 (ATCC 27815), serovar 6 (ATCC 27818) and serovar 14 (ATCC 33697)]. There were no mutations in the gyrA and gyrB genes; however, mutations were observed in the parC and parE genes. A point mutation in parC (Pro-57 Leu) and two novel mutations in parE (Ile-73 Thr and a methionine insertion at codon 86) were found.
L22 protein alterations of two U. parvum strains exhibiting resistance to erythromycin and one strain additionally resistant to azithromycin are shown in Table 1 . Strain Up-8 exhibited six amino acid alterations; strain Up-38, three alterations; and strain Up-71, six alterations. In a further erythromycin + azithromycin-resistant strain, no L22 protein changes were detected. No mutations were found (four strains) following sequence analyses of: (i) the two 23S rRNA operons; (ii) macrolide modification genes erm(A), erm(B), erm(C) and erm(E); or (iii) efflux pump genes msr(A), msr(B), msr(C) and msr(D).
Discussion
The integrase gene regions investigated were identical or very similar for five tetracycline-resistant strains, as were the tet(M) sequences for four strains. One strain harboured a diverse recombinant tet(M) gene. However, int-Tn and tet(M) genes from seven tetracycline-resistant ureaplasmas isolated at the Tygerberg Hospital, South Africa, in 2006, were seen to be highly diverse and mosaic in structure. 3 This may be attributed to the different geographical regions from which specimens were collected and according to prior tetracycline exposure.
14 Pretoria is located in the highveld, a 'closed community' setting with little tourist activity. The predominance of a single int-Tn/tet(M) gene type would be expected, the findings being similar to those of a recent Tunisian study. 15 In contrast, the earlier South African study was conducted in Tygerberg, which is in the vicinity of cosmopolitan Cape Town.
3 Cape Town is a major city with extensive national and international business, trade and tourism, which would result in the presence of multiple and diverse transposon and resistance gene types. To comprehensively assess the prevalence of tetracycline resistance and fully characterize the transposon/tet(M) gene types of U. parvum in South Africa, more extensive studies are required from other provinces/regions.
The most commonly reported resistance-mediating mutation, which is Ser83Leu in parC, as well as the triple mutation which was recently found to be associated with species-specific polymorphism in ureaplasmas, 16 were not identified in the ofloxacinresistant isolate. Therefore, the point mutation in parC and the two novel mutations in parE may be linked to the elevated ofloxacin MIC of 128 mg/L.
Although requiring further studies with additional isolates, some of the mutations observed in L22 proteins may have contributed to macrolide resistance. Xiao et al. 7 found three L22 protein point mutations that resulted in amino acid changes in three different U. parvum isolates, but these were stated to be atypical polymorphisms and not considered to contribute to macrolide resistance. Beeton et al.
2 reported a 6 bp deletion in the L4 protein to be associated with macrolide resistance, while Xiao et al. 7 described a five amino acid insertion in the extended loop of the L4 protein near the macrolide-binding site as contributing to macrolide resistance. No mutations in any of the gene targets employed for macrolide resistance assessment were detected in one strain that was coresistant to erythromycin and azithromycin; the mechanisms of resistance remain unknown.
The findings of U. parvum resistance to major antibiotics employed in sexually transmitted infection syndromic management approaches in South Africa, 17 lends to continued prevalence surveillance studies, with analyses of resistance development and resistance gene acquisitions.
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